13.26  -0.19 (-1.41%)		01-26 16:00
Open: 13.33 High: 13.435 Volume: 705,130		Pre. Close: 13.45 Low: 13.13 Market Cap: 1,485(M)

Short term
Mid term
Targets	6-month :	16.45	1-year :	17.69
Resists	First :	14.09	Second :	15.14
Pivot price	13.88
Supports	First :	12.38	Second :	10.3
MAs	MA(5) :	13.49	MA(20) :	13.71
	MA(100) :	12.95	MA(250) :	15.6
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	35.4	D(3) :	36.2
RSI	RSI(14): 47.7
52-week	High :	26.46	Low :	10.69

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVCR ] has closed above bottom band by 17.4%. Bollinger Bands are 10.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	13.44 - 13.53	13.53 - 13.61
Low:	12.96 - 13.04	13.04 - 13.12
Close:	13.13 - 13.27	13.27 - 13.39

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Sat, 24 Jan 2026
The Technical Signals Behind (NVCR) That Institutions Follow - Stock Traders Daily

Mon, 19 Jan 2026
NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat

Thu, 15 Jan 2026
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus

Thu, 15 Jan 2026
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga

Tue, 13 Jan 2026
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com

Tue, 13 Jan 2026
Why NovoCure Is Failing To Disrupt NSCLC (NASDAQ:NVCR) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	112 (M)
Shares Float	91 (M)
Held by Insiders	9.8 (%)
Held by Institutions	83.8 (%)
Shares Short	8,330 (K)
Shares Short P.Month	6,830 (K)

EPS	-1.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.04
Profit Margin	-27.7 %
Operating Margin	-21.6 %
Return on Assets (ttm)	-8.4 %
Return on Equity (ttm)	-50.6 %
Qtrly Rev. Growth	7.8 %
Gross Profit (p.s.)	4.33
Sales Per Share	5.73
EBITDA (p.s.)	-1.43
Qtrly Earnings Growth	0 %
Operating Cash Flow	-34 (M)
Levered Free Cash Flow	25 (M)

PE Ratio	-8.24
PEG Ratio	0
Price to Book value	4.34
Price to Sales	2.31
Price to Cash Flow	-43.07

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.